GO:0045843 negative regulation of striated muscle tissue development: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045843 describes any biological process that stops, prevents, or reduces the frequency, rate or extent of striated muscle tissue development.
• Myostatin (MSTN) is a canonical secreted inhibitor of skeletal muscle growth; loss of myostatin causes muscle hyperplasia and hypertrophy in mice.
• TGF-beta superfamily signaling, including myostatin, restrains myogenesis and is a major node for negative regulation of striated muscle tissue development.
• MicroRNAs fine-tune skeletal muscle development by repressing pro-myogenic transcripts, adding a post-transcriptional layer of negative regulation.
• Pathological muscle wasting in cancer cachexia and sarcopenia reflects an imbalance in which negative regulatory signals dominate over anabolic cues.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test whether candidate genes causally regulate striated muscle development.
Description
Striated muscle tissue development is a tightly orchestrated process that builds cardiac and skeletal muscle from progenitor cells. GO:0045843, negative regulation of striated muscle tissue development, captures the biological processes that stop, prevent, or reduce the frequency, rate or extent of this developmental program. Understanding this term is essential because the same inhibitory signals that sculpt muscle during embryogenesis can drive pathological muscle loss in adult disease. Negative regulation is not a single pathway but a network of secreted factors, transcription factors, and non-coding RNAs that converge on muscle progenitor proliferation and differentiation. The best-characterized negative regulator is myostatin (MSTN), a TGF-beta superfamily member that restrains skeletal muscle mass; mice lacking myostatin show a dramatic increase in muscle fiber number and size. Subsequent work has expanded the myostatin horizon to include cardiac and metabolic contexts, reinforcing that negative regulation of striated muscle development is a broad, multi-tissue process. At the same time, microRNAs have emerged as post-transcriptional brakes on myogenic gene expression, adding another layer of control. For researchers, GO:0045843 provides a conceptual framework to annotate genes, interpret transcriptomic and proteomic data, and design perturbation experiments that test causality in muscle development and disease.
negative regulation of striated muscle tissue development At A Glance
| GO ID | GO:0045843 |
|---|---|
| GO term | negative regulation of striated muscle tissue development |
| Ontology | biological_process |
| Synonym | down regulation of striated muscle development; down-regulation of striated muscle development; downregulation of striated muscle development; inhibition of striated muscle development |
| Major function | Restrains the initiation, rate, or extent of skeletal and cardiac muscle development |
| Representative regulator | Myostatin (MSTN), a TGF-beta superfamily ligand that limits muscle growth |
| Related signaling | TGF-beta superfamily signaling, myostatin signaling, microRNA-mediated repression |
| Disease relevance | Cancer cachexia, sarcopenia, cardiac hypertrophy and muscle wasting disorders |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:0045843?
GO:0045843 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle development. In practical terms, it includes signaling events, transcriptional programs, and post-transcriptional mechanisms that inhibit the formation, growth, or maturation of skeletal and cardiac muscle tissue. It is the inverse of positive regulation of striated muscle tissue development and is often studied through loss-of-function and gain-of-function experiments that alter muscle mass or differentiation.
Why Is negative regulation of striated muscle tissue development Important in Cell Biology?
Negative regulation of striated muscle tissue development is important because it determines muscle size, fiber type, and regenerative capacity, and its dysregulation underlies major human diseases including cancer cachexia, sarcopenia, and cardiac hypertrophy. The identification of myostatin as a secreted inhibitor of muscle growth established that muscle mass is actively restrained rather than merely built, and this principle now guides therapeutic strategies for muscle wasting.
• Defines the molecular brakes that prevent excessive or premature muscle differentiation during development.
• Myostatin loss-of-function increases muscle mass, showing that negative regulation is genetically tractable.
• TGF-beta superfamily signaling is a conserved inhibitory axis in skeletal and cardiac muscle.
• MicroRNAs provide post-transcriptional negative regulation of myogenic programs.
• Cancer cachexia involves systemic negative regulation of muscle mass and is a major clinical problem.
• Sarcopenia in aging reflects an imbalance between anabolic and catabolic signals in muscle.
• Cardiac hypertrophy is a maladaptive growth response in which negative regulatory pathways are overridden.
• Exercise and protein intake can partially counteract negative regulation of muscle mass.
• GO:0045843 supports functional annotation of muscle-related genes in genomic and transcriptomic studies.
• CRISPR-based perturbation of negative regulators enables causal testing in muscle disease models.
What Happens During negative regulation of striated muscle tissue development?
Secretion of inhibitory ligands
In simple terms: Cells release signals that tell muscle precursors to slow down or stop growing.
Negative regulation of striated muscle tissue development often begins with secreted ligands such as myostatin (MSTN), a TGF-beta superfamily member that restrains skeletal muscle mass. Myostatin is produced by muscle cells and acts in an autocrine and paracrine manner to limit progenitor proliferation and differentiation. The broader TGF-beta superfamily includes multiple ligands that can inhibit myogenesis, and their expression is dynamically regulated during development and in adult muscle homeostasis.
Receptor activation and intracellular signaling
In simple terms: The inhibitory signal binds to receptors on the cell surface and triggers a cascade inside the cell.
Myostatin and related TGF-beta ligands bind to type II and type I serine/threonine kinase receptors, leading to phosphorylation of SMAD2/3 and formation of SMAD complexes that translocate to the nucleus. These complexes regulate transcription of genes that suppress myogenic differentiation. This signaling axis is a central mechanism by which negative regulation of striated muscle tissue development is executed.
Transcriptional repression of myogenic programs
In simple terms: Inside the nucleus, inhibitory signals turn down the genes that build muscle.
Activated SMAD complexes and other inhibitory transcription factors repress the expression or activity of pro-myogenic factors such as MYOD1 and MYOG, reducing the frequency and extent of muscle differentiation. This transcriptional repression is a key step in negative regulation of striated muscle tissue development and can be reversed by exercise or anabolic stimuli.
Post-transcriptional control by microRNAs
In simple terms: Small RNA molecules can block the production of muscle-building proteins.
MicroRNAs regulate skeletal muscle development by repressing target mRNAs that promote myogenesis, adding a post-transcriptional layer of negative regulation. Specific microRNAs can inhibit myoblast differentiation and reduce muscle gene expression, and their dysregulation is associated with altered muscle phenotypes. This mechanism operates in parallel with secreted ligand signaling to fine-tune striated muscle development.
Integration with catabolic and anabolic pathways
In simple terms: Muscle size reflects a balance between signals that break down and signals that build up muscle.
Negative regulation of striated muscle tissue development is integrated with systemic catabolic states such as cancer cachexia and sarcopenia, where inflammatory and metabolic signals tip the balance toward muscle loss. Exercise and adequate protein intake can partially counteract these negative signals by promoting protein synthesis and muscle growth. In the heart, pathological hypertrophy involves growth-promoting pathways that override negative regulatory constraints, illustrating the importance of this balance in cardiac tissue.
Key Genes Involved in GO:0045843 negative regulation of striated muscle tissue development
The following genes and proteins are established or emerging players in negative regulation of striated muscle tissue development, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta superfamily ligand that inhibits skeletal muscle growth | Canonical negative regulator; knockout increases muscle mass |
| SMAD2 | Intracellular transducer of TGF-beta/myostatin signaling | Mediates transcriptional repression of myogenic genes |
| SMAD3 | Intracellular transducer of TGF-beta/myostatin signaling | Central node for inhibitory signaling in muscle |
| MYOD1 | Pro-myogenic transcription factor repressed by negative regulators | Readout of differentiation blockade |
| MYOG | Pro-myogenic transcription factor repressed by negative regulators | Marker of impaired differentiation |
| MEF2C | Transcription factor cooperating with myogenic factors | Target of inhibitory signaling |
| IGF1 | Anabolic growth factor opposing negative regulation | Counteracts muscle atrophy |
| AKT1 | Kinase promoting protein synthesis and muscle hypertrophy | Antagonizes negative regulation |
| FOXO1 | Transcription factor driving atrophy-related gene expression | Effector of catabolic signaling |
| FOXO3 | Transcription factor driving atrophy-related gene expression | Effector of catabolic signaling |
| TRIM63 | E3 ubiquitin ligase mediating muscle protein degradation | Marker of atrophy programs |
| FBXO32 | E3 ubiquitin ligase mediating muscle protein degradation | Marker of atrophy programs |
| MIR1 | MicroRNA that represses pro-myogenic targets | Post-transcriptional negative regulator |
| MIR133A | MicroRNA that modulates muscle development | Post-transcriptional negative regulator |
| MIR206 | MicroRNA involved in skeletal muscle development | Fine-tunes myogenic gene expression |
| TGFB1 | TGF-beta ligand with inhibitory effects on myogenesis | Broad negative regulator |
| ACVR2B | Type II receptor for myostatin and related ligands | Therapeutic target for muscle growth |
| INHBA | Activin ligand in TGF-beta superfamily | Modulates muscle mass |
How Is negative regulation of striated muscle tissue development Regulated?
Negative regulation of striated muscle tissue development is itself regulated at multiple levels. Myostatin expression and activity are modulated by exercise, nutritional status, and inflammatory cytokines, and its signaling through SMAD2/3 can be antagonized by anabolic pathways such as IGF1-AKT. MicroRNAs add another regulatory layer by repressing pro-myogenic transcripts. In disease states such as cancer cachexia and sarcopenia, systemic signals including inflammation and metabolic stress enhance negative regulation of muscle mass. In the heart, pathological hypertrophy involves growth and stress signaling that overrides negative regulatory constraints.
negative regulation of striated muscle tissue development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Cancer cachexia and muscle wasting | MSTN knockout mouse; overexpression in C2C12 cells |
| SMAD3 | Muscle atrophy and fibrosis | SMAD3 knockout or point-mutation models |
| FOXO3 | Sarcopenia and muscle atrophy | FOXO3 knockout or overexpression in muscle cells |
| MIR1 | Altered skeletal muscle development | MicroRNA knockout or overexpression models |
| ACVR2B | Muscle growth disorders | ACVR2B knockout or ligand trap models |
Cancer cachexia
Cancer cachexia is a multifactorial syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support. Negative regulation of striated muscle tissue development and homeostasis contributes to this muscle wasting, and cachexia is associated with poor prognosis and reduced quality of life. Research into myostatin and TGF-beta signaling has highlighted inhibitory pathways as potential therapeutic targets in cachexia.
Sarcopenia and aging
Sarcopenia is the age-related loss of muscle mass and function, and it reflects an imbalance between anabolic and catabolic signals in skeletal muscle. Strategies to prevent sarcopenia include protein intake and exercise, which can partially counteract negative regulatory influences on muscle. Understanding GO:0045843 helps frame sarcopenia as a failure to overcome inhibitory signals on muscle maintenance.
Cardiac hypertrophy and heart disease
Pathological cardiac hypertrophy is a maladaptive growth response of the heart that involves activation of growth and stress signaling pathways. Negative regulatory mechanisms that normally constrain striated muscle development may be overridden in hypertrophy, contributing to heart failure. Studying these pathways is important for identifying therapeutic targets in cardiac disease.
From negative regulation of striated muscle tissue development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate negative regulator increase muscle mass? | CRISPR knockout in mouse or cell line |
| Does a specific point mutation alter inhibitory signaling? | CRISPR point-mutation knock-in |
| Can a tagged version of the protein be used to track localization? | Tagged knock-in |
| Does overexpression of a negative regulator reduce myogenesis? | Overexpression cell model |
| Which microRNAs repress pro-myogenic transcripts? | MicroRNA knockout or overexpression |
| How does exercise counteract negative regulation? | In vivo exercise model with molecular readouts |
How to Study the negative regulation of striated muscle tissue development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript abundance | Identify genes repressed by negative regulators |
| Proteomics | Protein abundance and modifications | Map signaling effectors |
| Phosphoproteomics | Kinase activity and signaling nodes | Measure SMAD activation |
| Immunofluorescence | Protein localization and fiber morphology | Assess differentiation and fiber size |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| qPCR | mRNA levels of target genes | Quantify myogenic and atrophy markers |
| CRISPR screening | Gene function at scale | Discover novel negative regulators |
| Bioinformatics | Pathway and network analysis | Interpret omics data in GO context |
Transcriptomic profiling
RNA-seq can quantify changes in myogenic and atrophy-related gene expression following perturbation of negative regulators, providing a global view of how GO:0045843 is executed. Comparing knockout and wild-type muscle or myoblast cultures reveals transcriptional programs repressed by inhibitory signals.
Proteomic and phosphoproteomic analysis
Proteomics can measure protein abundance and post-translational modifications in muscle tissue, including SMAD phosphorylation downstream of myostatin signaling. These methods help identify effectors of negative regulation of striated muscle tissue development.
Imaging and histology
Immunofluorescence and histology can assess muscle fiber size, number, and differentiation markers such as MYOD1 and MYOG in models of altered negative regulation. Imaging provides spatial context for gene expression changes.
Functional assays
Myoblast differentiation assays, proliferation assays, and muscle strength measurements in vivo can test the functional consequences of manipulating negative regulators. These assays link molecular changes to muscle phenotype.
How CRISPR Can Be Used to Study GO:0045843 negative regulation of striated muscle tissue development
Knockout
CRISPR knockout of negative regulators such as MSTN can be used to test whether loss of function increases muscle mass or differentiation, as demonstrated in myostatin knockout mice. Knockout models are essential for establishing causality in GO:0045843.
Point Mutation
Point mutations can be introduced to dissect specific residues required for inhibitory signaling, such as phosphorylation sites in SMAD proteins. These models help distinguish loss-of-function from gain-of-function mechanisms.
Knock-in
Knock-in of tags or reporters allows tracking of negative regulator expression and localization in muscle tissue. This approach is useful for studying dynamic changes during development and disease.
Overexpression
Overexpression of negative regulators or microRNAs can suppress myogenesis and reduce muscle gene expression, providing a gain-of-function counterpart to knockout studies. Overexpression models are valuable for testing therapeutic hypotheses.
How EDITGENE Supports negative regulation of striated muscle tissue development Research
Researchers studying negative regulation of striated muscle tissue development-related genes often need to determine whether a candidate gene is causally involved in restraining muscle growth or differentiation. EDITGENE provides CRISPR-based cell and animal models to test these hypotheses with precision.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of striated muscle tissue development research.
Frequently Asked Questions About negative regulation of striated muscle tissue development
What is GO:0045843?
GO:0045843 is the Gene Ontology term for negative regulation of striated muscle tissue development, defined as any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle development.
What genes are involved in negative regulation of striated muscle tissue development?
Key genes include MSTN, SMAD2, SMAD3, MYOD1, MYOG, and microRNAs such as MIR1 and MIR133A.
How does myostatin inhibit muscle growth?
Myostatin is a secreted TGF-beta superfamily ligand that activates SMAD2/3 signaling to repress myogenic transcription and limit muscle mass.
What diseases are linked to negative regulation of striated muscle tissue development?
Cancer cachexia, sarcopenia, and cardiac hypertrophy are associated with dysregulated negative regulation of muscle.
What research methods study GO:0045843?
RNA-seq, proteomics, immunofluorescence, and CRISPR knockout or overexpression models are commonly used.
Can CRISPR knockout increase muscle mass?
Knockout of myostatin in mice increases muscle fiber number and size, demonstrating that removing a negative regulator can enhance muscle growth.
What is the role of microRNAs in muscle development?
MicroRNAs post-transcriptionally repress pro-myogenic transcripts, adding a layer of negative regulation to skeletal muscle development.
How is sarcopenia related to negative regulation of muscle?
Sarcopenia reflects an imbalance in which negative regulatory and catabolic signals dominate over anabolic signals in aging muscle.
What is cancer cachexia?
Cancer cachexia is a multifactorial syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support.
How can I study negative regulators of muscle development in my lab?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, and library screening services to test candidate genes.
Conclusion
GO:0045843, negative regulation of striated muscle tissue development, provides a framework for understanding the inhibitory signals that constrain muscle growth and differentiation. From myostatin and TGF-beta signaling to microRNA-mediated repression, these mechanisms are critical for normal development and are dysregulated in cancer cachexia, sarcopenia, and cardiac disease. CRISPR-based models and multi-omics methods enable researchers to test causality and identify therapeutic targets within this process.
References
- 1. Fearon K et al.. 2011. Definition and classification of cancer cachexia: an international consensus.. Lancet Oncol 12(5):489-95 PMID: 21296615
- 2. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 3. Schiaffino S et al.. 2013. Mechanisms regulating skeletal muscle growth and atrophy.. FEBS J 280(17):4294-314 PMID: 23517348
- 4. Tipton KD et al.. 2001. Exercise, protein metabolism, and muscle growth.. Int J Sport Nutr Exerc Metab 11(1):109-32 PMID: 11255140
- 5. Rogeri PS et al.. 2021. Strategies to Prevent Sarcopenia in the Aging Process: Role of Protein Intake and Exercise.. Nutrients 14(1) PMID: 35010928
- 6. McPherron AC et al.. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.. Nature 387(6628):83-90 PMID: 9139826
- 7. Sharma M et al.. 2015. Myostatin: expanding horizons.. IUBMB Life 67(8):589-600 PMID: 26305594
- 8. Wang J et al.. 2018. Effects of microRNAs on skeletal muscle development.. Gene 668:107-113 PMID: 29775754
